CTX112 Trial
Phase 1
80
about 6.8 years
18–70
6 sites in CA, IA, IL +3
What this study is about
Researchers are testing the safety and preliminary effectiveness of CTX112 in adults with autoimmune diseases like lupus, scleroderma, or inflammatory muscle disease. The trial will last for 2487 days and involve approximately 80 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CTX112
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: To assess the pharmacodynamic response of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM, To assess the pharmacokinetics (PK) of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM
Immune